Introduction
============

Primary nephrotic syndrome (PNS) is the most common chronic kidney disease in children and is also the main cause of chronic renal failure in adults in China ([@b1-etm-0-0-8698],[@b2-etm-0-0-8698]). Previous studies have found that the cause of chronic kidney diseases in adults originates from PNS during childhood, which can be alleviated by treatment ([@b3-etm-0-0-8698],[@b4-etm-0-0-8698]). The etiology and pathogenesis of childhood PNS remain unclear. However, it is well-documented that proteinuria, hypoproteinemia, hyperlipidemia and edema are the main pathophysiological characteristics associated with PNS, with proteinuria being the core change ([@b2-etm-0-0-8698],[@b5-etm-0-0-8698]). Damage to the glomerular filtration barrier is the direct cause of proteinuria, where the abnormal number or function of podocytes are a cause of pathological changes in glomerular filtration membrane permeability, proteinuria formation and ultimately glomerular sclerosis ([@b6-etm-0-0-8698],[@b7-etm-0-0-8698]). Podocyte injuries have been reported to participate in the formation of urinary fistula and glomerular sclerosis, such that signs of podocyte injury have been observed in the urine of patients with primary and secondary glomerular disease ([@b8-etm-0-0-8698],[@b9-etm-0-0-8698]). Additionally, previous studies have found that a variety of factors, including anti-capsular antibodies, metabolic factors, hemodynamics and infection, can result in podocyte damage ([@b10-etm-0-0-8698],[@b11-etm-0-0-8698]).

Interleukin (IL)-17 is a proinflammatory cytokine secreted by Th17 cells ([@b12-etm-0-0-8698]) that promotes the secretion of IL-1β, tumor necrosis factor (TNF)-α and IL-6 by binding to their corresponding receptors mainly expressed in the epithelial and endothelial cells of the kidney and spleen ([@b13-etm-0-0-8698]). Previous studies have found that the IL-23/IL-17 pathway contributes significantly to renal tissue injury in experimental glomerulonephritis ([@b16-etm-0-0-8698]) and patients with PNS ([@b17-etm-0-0-8698]), where the inhibition of IL-17 expression in patients with renal disease attenuated crescent formation in nephrotoxic serum nephritis ([@b18-etm-0-0-8698]). However, it currently remains unclear whether IL-17 can influence the development of PNS by regulating podocyte injury.

In the present study, the relationship between IL-17 and PNS, specifically that between IL-17 and inflammatory podocyte injury, were investigated. It was found that IL-17 was highly expressed in renal tissues of patients with PNS and was associated with indicators of podocyte injury. In addition, IL-17 induced podocyte apoptosis by activating the Fas/Fas ligand (FasL)/caspase-8/caspase-3 apoptotic pathway via NF-κB activation *in vitro*. In conclusion, data from the present study provided a potential target for attenuating podocyte injury in children with PNS by suppressing inflammation.

Materials and methods
=====================

### Tissues and ethics statement

Renal biopsies of 9 patients with minimal change nephrotic syndrome (MCNS) (3 female and 6 males; mean age, 8.6±2.3 years), 15 patients with mesangial proliferative glomerulonephritis (MsPGN) (6 females and 9 males; mean age, 8.2±2.4 years) and 9 patients with focal segmental glomerulosclerosis (FSGS) (3 females and 6 males; mean age, 8.4±2.8 years) were collected at The First Hospital of Jilin University (Changchun, China) from January 2015 to December 2017. In addition, normal kidney tissues were collected from 15 patients (6 females and 9 males, age range, 3-10 years, mean age, 8.5±3.0 years) at The First Hospital of Jilin University (Jilin, China) during early renal tumor surgery; normal routine urine test results and renal function were observed. The inclusion criteria used were as follows: i) All PNS patients were diagnosed according to the diagnostic criteria for glomerular nephropathy in China ([@b19-etm-0-0-8698]); ii) patients with PNS were \<10 years of age and did not receive any medication prior to renal puncture; iii) the patients with PNS has complete clinical data, including age and sex data. The exclusion criteria were as follows: i) Other organ tissue dysfunction; ii) Infected with HIV, HCV or tuberculosis; iii) had received surgical treatment within half a year; iv) exhibited epilepsy, congenital heart disease or any other genetic diseases. All relevant guardians or patients of the participants in the present study provided signed informed consent and the experiments were approved by the Ethics Association of The First Hospital of Jilin University (Changchun, China). No animals were used in the present study.

### Cell lines and drugs

Podocytes ([@b20-etm-0-0-8698],[@b21-etm-0-0-8698]), from H-2Kb-tsA58 transgenic mice, were a gift from Professor Peter Mundel (Mount Sinai School of Medicine, New York University, USA) and were cultured at 37˚C with 5% CO~2~ in DMEM (cat. no. 12491-15; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (cat. no. 10100-147; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin (cat. no. 1564005; Thermo Fisher Scientific, Inc.).

A total of 1.5x10^6^ cells/well of podocytes were seeded into six-well plates and were treated with 0, 50, 100 and 200 ng/ml recombinant mouse IL-17 (rmIL-17; cat. no. PMC0175; Thermo Fisher Scientific, Inc.) for 24, 48 or 72 h. A total of 5 µM helenalin (cat. no. 6754-13-8; Cayman Chemical Company) was added to podocytes with 200 ng/ml rmIL-17 for 72 h. Cell culture supernatant was collected using centrifugation (2,000 x g; 10 min; 4˚C), and the concentration of IL-1β in the cell culture supernatant was subsequently measured using the IL-1β mouse uncoated ELISA kit (cat. no. 88-7013-88; Thermo Fisher Scientific, Inc.) and TNF-α was measured using the TNF-α mouse ELISA kit (cat. no. BMS607-3; Thermo Fisher Scientific, Inc.).

### Reverse transcription-quantitative PCR (RT-qPCR)

TRIzol^®^ (cat. no. 15596018; Thermo Fisher Scientific, Inc.) was used to extract total RNA from kidney tissues or cells. The extracted RNA was then reverse transcribed into cDNA by using PrimeScript^™^ RT Master Mix (cat. no. RR036B; Takara Biotechnology Co., Ltd.), with the temperature protocol of 37˚C for 60 min and 85˚C for 5 sec. Subsequently, 20 µl fluorescence quantitative PCR (qPCR) reactions were prepared according to the manufacturer\'s protocol of the SYBR^®^-Green qPCR Master Mix (cat. no. 638320; Takara Biotechnology Co., Ltd.) and amplified using ABI 7500 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used: Initial denaturation at 95˚C for 30 sec, followed by 40 cycles of 90˚C for 5 sec and 65˚C for 30 sec. Sequences of all primers used for RT-qPCR analysis are provided in [Table I](#tI-etm-0-0-8698){ref-type="table"}. We used the 2^-ΔΔCq^ method ([@b22-etm-0-0-8698]) to calculate the relative expression levels of genes, and GAPDH was used for normalization.

### Western blotting

Tissues and cells were submerged in RIPA lysate (cat. no. P0013C; Beyotime Institute of Biotechnology), and detected protein concentration using a BCA kit (cat. no. P0012; Beyotime Institute of Biotechnology), and a total of 40 µg protein were separated by 5% SDS-PAGE and then transferred to PVDF membranes. BSA (5%) which was 5% BSA buffer solution (cat. no. ST-023; Beyotime Institute of Biotechnology) in PBS as a blocking solution to block for 1 h at room temperature, and then washed 3 times with PBS buffer. Membranes were subsequently incubated with primary antibodies against IL-17 (cat. no. sc-374218; 1:500; Santa Cruz Biotechnology, Inc.), Fas (cat. no. ab82419; 1:1,000; Abcam), FasL (cat. no. ab15285; 1:1,000; Abcam), active caspase-8 (cat. no. ab227430; 1:2,000; Abcam), active caspase-3 (cat. no. ab49822; 1:500; Abcam), p65 phosphorylated (p-) S636 (cat. no. ab86299; 1:5,000) or GAPDH (cat. no. ab9484; 1:3,000) overnight at 4˚C, followed by incubation with Goat Anti-Rabbit IgG H&L (HRP) (cat. no. ab6721; 1:1,000) or Goat Anti-Mouse IgG H&L (HRP) (cat. no. ab205719; 1:1,000) secondary antibodies for 1 h at room temperature, and then ECL solution (cat. no. WBKLS0100, Beijing Xinjingke Biotechnologies Co., Ltd.) was added for detection. Protein expression levels were analyzed using ImageJ v1.8.0 (National Institutes of Health), with the calculated gray scale values of target proteins/GAPDH used to quantify relative expression.

### Immunohistochemistry

IL-17 protein expression was detected by immunohistochemical staining according to the protocol of the VECTASTAIN^®^ Elite^®^ ABC Kit (Vector Laboratories, Inc.; Maravai LifeSciences) in the kidney tissue sections. The 5 µm paraffin sections were incubated at 60˚C for 2 h after soaking in 3% hydrogen peroxide solution, dewaxed and hydrated using xylene and an ethanol gradient, following which sections were washed with PBS and double distilled water. 5% BSA which was 5% BSA buffer solution in PBS as a blocking solution to block for 1 h at room temperature. The sections were subsequently stained using an anti-IL-17 primary antibody (1:100; cat. no. sc-374218; Santa Cruz Biotechnologies, Inc.) or PBS (negative control) overnight at 4˚C, followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG H&L secondary antibodies (cat. no. ab6721; 1:500; Abcam) at 37˚C for 2 h. Finally, DAB staining (cat. no. P0203; Beyotime Institute of Biotechnology) for 10 min at room temperature and hematoxylin staining at room temperature (cat. no. C0107; Beyotime Institute of Biotechnology) for 2 min, and images from 5 fields of view were obtained per slice. The sections were analyzed using Leica TCS SP5 microscope 217 (magnification, x200; Leica Microsystems, Ltd.) with LAS AF Lite 4.0 image browser software (Leica Microsystems, Ltd.). The cells were either stained yellow (1 point), brown (2 points) or tan (3 points) for positive staining. In addition, ≤25% positive cells in each field of view was scored as 0 point, 25-75% was scored as 1 point and ≥75% was scored as 2 points. Final immunohistochemical score=Score (staining intensity) x Score (% of IL-17 positive cells) ([@b23-etm-0-0-8698]).

### Urine podocyte counting

Following admission, each patient provided 50 ml clean mid-stream morning urine 2 days prior to renal puncture. Urine samples were subsequently centrifuged at 1,000 x g for 10 min at room temperature to harvest the urine sediments. A total of 50 µl urine sediment which was dissolved in physiological saline solution was added into an auto-smear centrifuge (TXD3; Changsha Xiangyi Centrifuge Instrument Co., Ltd.) to produce cell slides by centrifugation (350 x g, 3 min, room temperature). The slides were then dried at room temperature and fixed with 99.5% acetone for 4 min at room temperature before being and air-dried.

Slides with cells were incubated in culture plates and washed with PBS (3x3 min), followed by fixation with 4% paraformaldehyde for 15 min at room temperature and permeabilization with 0.5% Triton X-100 dissolved in PBS. Normal 5% goat serum (cat. no. C0265; Beyotime Institute of Biotechnology) was then added onto the slides for blocking at room temperature for 30 min before Anti-PODXL antibody \[EPR9518\] (cat. no. ab150358; 1:1,000; Abcam) was added into slides and incubated in a wet box overnight at 4˚C. The next day, the slides were rinsed three times with PBS supplemented with 0.05% Tween-20 (PBS-T), following which Goat Anti-Rabbit IgG H&L (Alexa Fluor^®^ 488; cat. no. ab150077; 1:1,000; Abcam) was added and the slides were incubated in a wet box at 20-37˚C for 1 h. A concentration of 5 µg/ml DAPI (cat. no. 4083; Cell Signaling Technology, Inc.) was subsequently added before the slides were incubated in the dark for 5 min at room temperature to stain the nuclei of the specimen. Following the removal of excess DAPI by rinsing with PBS-T (4x5 min), the slides were dried using absorbent paper and an anti-fluorescence quenching sealant (cat. no. HCY078; Hangzhou Yuxin Biotechnology Co., Ltd.) was used. A fluorescence microscope was then used to acquire images. Counting the average of urinary podocytes were counted from 10 high-powered (magnification, x200) fields of view.

### Flow cytometric analysis of apoptosis

Total of 2-3x10^6^ cells/well of podocytes were collected following treatment for 24, 48 and 72 h with 0, 50, 100 and 200 ng/ml IL-7 and the Annexin V-FITC/propidium iodide kit (cat. no. V13241; Invitrogen; Thermo Fisher Scientific, Inc.) was used to detect apoptosis according to manufacturer\'s protocol. Beckman CytoFLEX Flow cytometer (Beckman Coulter, Inc.) with Flowjo 10.0 software (Beckman Coulter, Inc.) was used to analyze podocyte apoptosis.

### Statistical analysis

Data are presented as the mean ± standard deviation from three independent repetitions per experiment and were analyzed using SPSS 20.0 (IBM Corp.). Unpaired Student\'s t-test was used to compare differences between two groups, whilst comparison between multiple groups was performed using the One-way ANOVA followed by Duncan\'s tests. Correlation between two groups was analyzed by Pearson\'s correlation analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### IL-17 is highly expressed in patients with PNS

RT-qPCR was used to measure the expression of IL-17 mRNA, whereas western blotting and immunohistochemistry were performed for IL-17 protein expression in patient tissue samples. The expression of IL-17 in renal tissues of patients with PNS was found to be significantly higher compared with that of normal kidney tissues ([Fig. 1A](#f1-etm-0-0-8698){ref-type="fig"} and [B](#f1-etm-0-0-8698){ref-type="fig"}). In addition, the expression level of IL-17 also appeared to associate with disease severity in patients with PNS ([Fig. 1C](#f1-etm-0-0-8698){ref-type="fig"}), as IL-17 expression was found to be highest in renal tissues of patients with FSGS (n=9) and lowest in MCNS (n=9). Taken together, IL-17 was highly expressed in the renal tissues of patients with PNS and was associated with the severity of PNS in patients.

### IL-17 is associated with podocyte injury in patients with PNS

Podocalyxin (PCX) is a podocyte-specific marker protein ([@b24-etm-0-0-8698]). Podocytes in the urine are derived from podocytes shed from kidney tissue ([@b25-etm-0-0-8698]) and PCX levels can be related to podocyte injury. The expression of PCX mRNA in kidney tissue of patients with PNS was measured using RT-qPCR and the number of podocytes (MCNS was 1.67±0.38, MsPGN was 7.06±0.72, FSGS was 10.44±0.69) was counted using immunofluorescence detection of PCX proteins ([Fig. 2A](#f2-etm-0-0-8698){ref-type="fig"} and [C](#f2-etm-0-0-8698){ref-type="fig"}). It was found that there was a negative correlation between IL-17 and PCX mRNA expression in the renal tissue ([Fig. 2B](#f2-etm-0-0-8698){ref-type="fig"}), whilst a positive correlation was found between IL-17 mRNA expression and the number of urinary podocytes in patients with PNS ([Fig. 2D](#f2-etm-0-0-8698){ref-type="fig"}). The results suggest that the expression of IL-17 was correlated with podocyte injury in patients with PNS.

### IL-17 induces podocyte apoptosis in vitro

Flow cytometry was used to measure apoptosis in podocytes following the addition of ascending concentrations (0, 50, 100 and 200 ng/ml) of rmIL-17 to the culture medium. After 24, 48 and 72 h treatment, podocytes were collected for analysis of apoptosis and gene expression. For each dose of rmIL-17, the apoptotic rate of podocytes increased with increasing culture time ([Fig. 3A](#f3-etm-0-0-8698){ref-type="fig"}). Furthermore, at each time point the apoptotic rate of podocytes increased as the rmIL-17 dose increased ([Fig. 3A](#f3-etm-0-0-8698){ref-type="fig"}). These observations suggested that IL-17 induced podocyte apoptosis *in vitro* in a time- and dose-dependent manner.

According to the experimental results obtained in [Fig. 3A](#f3-etm-0-0-8698){ref-type="fig"}, a dose of 200 ng/ml rmIL-17 for a treatment of 72 h was chosen for subsequent experiments. The mRNA expression of podocyte marker molecules, WT1, nephrin, synaptopodin and podocalyxin were significantly reduced following IL-17 treatment ([Fig. 3B](#f3-etm-0-0-8698){ref-type="fig"}). In addition, IL-17 treatment increased the expression of Fas, FasL, active-caspase-8 and active-caspase-3 proteins ([Fig. 4](#f4-etm-0-0-8698){ref-type="fig"}). These results suggested that IL-17 induced podocyte apoptosis by activating the Fas/FasL/caspase-8/caspase-3 signaling pathway in podocytes *in vitro*.

### IL-17 activates the NF-κ signaling pathway in podocytes in vitro

The phosphorylation of p65 subunit of NF-κB was increased following IL-17 treatment ([Fig. 4](#f4-etm-0-0-8698){ref-type="fig"}), suggesting that the NF-κB pathway was activated ([@b26-etm-0-0-8698]). Since this signaling pathway controls the transcription of a plethora of genes associated with inflammation ([@b27-etm-0-0-8698]), the hypothesis that IL-17 induced podocyte apoptosis by upregulating inflammation was first tested, by measuring the levels IL-1β and TNF-α content in the podocyte culture supernatant following IL-17 treatment. IL-17 treatment increased the secretion of IL-1β and TNF-α in a time- and dose-dependent manner ([Fig. 5A](#f5-etm-0-0-8698){ref-type="fig"} and [B](#f5-etm-0-0-8698){ref-type="fig"}). To investigate the relationship between IL-17-induced podocyte apoptosis, IL-1β and TNF-α secretion and the NF-κB pathway, podocytes were treated with helenalin, a NF-κB inhibitor, in the presence of IL-17. Helenalin significantly attenuated IL-17-induced podocyte apoptosis ([Fig. 5C](#f5-etm-0-0-8698){ref-type="fig"}), and IL-1β ([Fig. 5D](#f5-etm-0-0-8698){ref-type="fig"}) and TNF-α ([Fig. 5E](#f5-etm-0-0-8698){ref-type="fig"}) secretion by podocytes. Additionally, helenalin also significantly inhibited IL-17-activated NF-κB signaling via p65 phosphorylation and the Fas/FasL/caspase-8/caspase-3 apoptotic pathway ([Fig. 4](#f4-etm-0-0-8698){ref-type="fig"}). These results suggested that IL-17-induced podocyte apoptosis may be associated with the NF-κB signaling pathway.

Discussion
==========

Over the past two decades, studies have found that among children with PNS, the incidence of FSGS has exhibited an increasing trend, seriously affecting the prognosis of patients with PNS ([@b28-etm-0-0-8698],[@b29-etm-0-0-8698]). However, development of treatment strategies for PNS is hindered by the poorly understood mechanism of glomerular sclerosis pathogenesis. It has been previously reported that inflammation mediated by CD4^+^ T cell dysfunction is associated with the occurrence of glomerular sclerosis ([@b30-etm-0-0-8698],[@b31-etm-0-0-8698]). Traditionally, CD4^+^ T cells are divided into Th1 and Th2 subtypes. Th1 cells are mainly associated with the secretion of cytokines IL-2 and IFN-γ, which mediate cellular immune responses, whereas Th2 mainly secrete cytokines IL-4 and IL-10, which mediate fluid immune responses ([@b32-etm-0-0-8698],[@b33-etm-0-0-8698]). Although some studies have demonstrated that the dysfunction of Th1/Th2 and the dominant activation of Th2 serve an important role in the development of kidney disease ([@b34-etm-0-0-8698],[@b35-etm-0-0-8698]); however, other studies have opposing views ([@b36-etm-0-0-8698],[@b37-etm-0-0-8698]). Therefore, the balance of Th1/Th2 activation alone is not sufficient to fully explain the mechanism of glomerular sclerosis pathogenesis.

In recent years, Th17 cells were discovered as additional CD4^+^ T cells, which have a different mechanism of differentiation, but phenotypes and functions are derived from Th1/Th2([@b38-etm-0-0-8698]). IL-17 is an important cytokine secreted by Th17 cells, which has been found to associate closely with the development of coronary heart disease ([@b39-etm-0-0-8698],[@b40-etm-0-0-8698]), multiple sclerosis ([@b41-etm-0-0-8698]), inflammation and autoimmune diseases ([@b15-etm-0-0-8698]). In kidney diseases, Matsumoto *et al* ([@b42-etm-0-0-8698]) found that the excretion of IL-17 in urine during the minimally active period was significantly higher compared with that in the remission period, which was in turn proportional to the excretion of urinary protein. In addition, IL-17 was also found to be associated with renal tissue injury in experimental glomerulonephritis ([@b16-etm-0-0-8698]), patients with PNS ([@b17-etm-0-0-8698]) and the severity of IgA nephropathy ([@b43-etm-0-0-8698]). In the present study, it was found that the expression of IL-17 in the renal tissues of patients with PNS was significantly higher compared with that of normal kidney tissues, which was also associated with the severity of disease in patients with PNS. In addition, it was found that IL-17 expression was associated with indicators of podocyte injury.

Podocytes damage is a signature of nephrotic syndrome ([@b44-etm-0-0-8698],[@b45-etm-0-0-8698]). Podocytes are glomerular visceral epithelial cells, which belong to a class of terminally differentiated cells. When podocytes are damaged, the normal structure of the foot processes is destroyed, resulting in podocytes detaching from the basement membrane. Since this cannot be repaired effectively due to the limited proliferative ability of podocytes ([@b44-etm-0-0-8698]), the integrity of the glomerular filtration membrane is compromised, leading to proteinuria. In the present study, it was found *in vitro* that IL-17 treatment induced podocyte apoptosis in addition to reducing the mRNA expression of podocyte-specific markers, including WT1, nephrin, synaptopodin and podocalyxin. Indeed, expression of these markers were directly associated with podocyte integrity, where studies have found that the loss or mutation of podocalyxin leads to the development of FSGS and familial nephrotic syndrome ([@b46-etm-0-0-8698],[@b47-etm-0-0-8698]). Additionally, Fluvastatin treatment, which is mainly used to treat primary hypercholesterolemia and primary mixed dyslipidemia, protects podocytes in HIV-associated nephropathy by increasing the expression of nephrin, WT1 and synaptopodin ([@b48-etm-0-0-8698],[@b49-etm-0-0-8698]).

To explore the molecular mechanism by which IL-17 induces podocyte apoptosis further, changes in protein expression in cultured podocytes following IL-17 treatment were examined. IL-17 treatment increased the expression of Fas, FasL, active-caspase-8, active-caspase-3 in addition to p65 phosphorylation, all of which were reversed by concomitant treatment with the NF-κB inhibitor helenalin. A previous study has shown that inflammatory factors can induce muscle cell apoptosis by activating the Fas/FasL-caspase-8-caspase-3 pathway ([@b50-etm-0-0-8698]). NF-κB signaling controls the transcription of a variety of genes associated with inflammation, including IL-1β and TNF-α, which in turn can potentiate NF-κB signaling further ([@b51-etm-0-0-8698]). Therefore, it is possible that IL-17 first increased the secretion of IL-1β and TNF-α by activating the NF-κB pathway in podocytes, where these inflammatory factors increased podocyte apoptosis of by activating the Fas/FasL-caspase-8-caspase-3 pathway.

However, it should be emphasized that some limitations exist for the present study. The podocytes used in the *in vitro* study were cell lines and not primary cells. Secondly, the sample size of the tissues collected from each disease group were small. In addition, inhibitors for the related signaling pathways mentioned in the present study were not used.

In conclusion, results from the present study suggested that IL-17 was highly expressed in renal tissues of patients with PNS. The Fas/FasL/caspase-8/caspase-3 apoptotic pathway was activated in a NF-κB-dependent manner to induce podocyte apoptosis.
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![Comparison of IL-17 expression in kidney tissues from patients with and without PNS. (A) Reverse transcription-quantitative PCR was performed to detect the expression of IL-17 mRNA. (B) Western blotting was performed to measure the expression of IL-17 protein in the kidney tissues of patients without PNS (n=15), with MCNS (n=9), MsPGN (n=15) or FSGS (n=9). (C) Representative images of immunohistochemical staining displaying IL-17 protein expression in kidney tissues from the four groups of patients (magnification, x200). IL-17, interleukin-17; PNS, primary nephrotic syndrome; MCNS, minimal change nephrotic syndrome; MsPGN, mesangial proliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis.](etm-20-01-0409-g00){#f1-etm-0-0-8698}

![IL-17 is associated with podocyte injury markers in patients with PNS. (A) Reverse transcription-quantitative PCR was performed to measure the expression of PCX mRNA in the kidney tissues of normal patients without PNS (n=15), and of patients with MCNS (n=9), MsPGN (n=15) and FSGS (n=9). (B) IL-17 mRNA was negatively correlated with PCX mRNA expression in the kidney tissues of PNS patients (n=33). (C) The number of urinary podocytes in patients with MCNS (n=9), MsPGN (n=15) and FSGS (n=9). (D) A positive correlation was observed between the levels of IL-17 mRNA in renal tissues and the number of urinary podocytes in patients with PNS (n=33). IL-17, interleukin-17; PNS, primary nephrotic syndrome; MCNS, minimal change nephrotic syndrome; MsPGN, mesangial proliferative glomerulonephritis; FSGS, focal segmental glomerulosclerosis; PCX, podocalyxin; HP, high power fields.](etm-20-01-0409-g01){#f2-etm-0-0-8698}

![IL-17 induces podocyte apoptosis and affects the expression of podocyte markers *in vitro*. (A) IL-17 induced podocyte apoptosis *in vitro* in a time- and dose-dependent manner, based on flow cytometric analysis. ^\*\*\*^P\<0.001 vs. 0 ng/ml. (B) Reverse transcription-quantitative PCR was performed to measure mRNA expression of WT1, nephrin, synaptopodin and podocalyxin. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 vs. WT group. Data are presented as the mean ± standard deviation from three independent repetitions per experiment. WT, wild-type; WT1, Wilm\'s tumor 1; IL-17, interleukin-17; rmIL-17, recombinant mouse IL-17.](etm-20-01-0409-g02){#f3-etm-0-0-8698}

![IL-17 activates the NF-κB and Fas/FasL/caspase-8/caspase-3 signaling pathways in podocytes *in vitro*. Western blot analysis was performed to measure the protein levels of Fas, FasL, active-caspase-8, active-caspase-3, p65 and p-p65 in cultured podocytes following IL-17 and/or helenalin treatment. Data are presented as the mean ± standard deviation from three independent repetitions per experiment. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 vs. IL-17. FasL, Fas ligand; p-, phosphorylated.](etm-20-01-0409-g03){#f4-etm-0-0-8698}

![NF-κB inhibition by helenalin attenuates IL-17-induced podocyte apoptosis and secretion of IL-1β or TNF-α by podocytes. IL-17 induced the secretion of (A) IL-1β and (B) TNF-α *in vitro* in a time- and dose-dependent manner. ^\*\*\*^P\<0.001 vs. 0 ng/ml. (C) NF-κB inhibitor helenalin attenuated IL-17-induced podocyte apoptosis. Helenalin attenuated IL-17-induced the secretion of (D) IL-1β and (E) TNF-α. Data are presented as the mean ± standard deviation from three independent repetitions per experiment. IL, interleukin; TNF-α, tumor necrosis factor-α.](etm-20-01-0409-g04){#f5-etm-0-0-8698}

###### 

Sequences of primers used for reverse transcription-quantitative PCR.

  Gene                   Primer sequence (5\'-3\')   
  ---------------------- --------------------------- ------------------------
  IL-17                  F:                          TCCCACGAAATCCAGGATGC
  R:                     GGATGTTCAGGTTGACCATCAC      
  Podocalyxin (human)    F:                          TCCCAGAATGCAACCCAGAC
  R:                     GGTGAGTCACTGGATACACCAA      
  Podocalyxin (murine)   F:                          AGTGCCACAACATCAACAGAA
  R:                     TGTGAATGGTGTAGGGTTGCT       
  WT1                    F:                          AGCACGGTCACTTTCGACG
  R:                     GTTTGAAGGAATGGTTGGGGAA      
  Nephrin                F:                          ATGGGAGCTAAGGAAGCCACA
  R:                     CCACACCACAGCTTAACTGTC       
  Synaptopodin           F:                          TCCTCACCTAATGCCACACTC
  R:                     GCTGGAGGGTTTTGGTTGATA       
  GAPDH (human)          F:                          ACAACTTTGGTATCGTGGAAGG
  R:                     GCCATCACGCCACAGTTTC         
  GAPDH (murine)         F:                          AGGTCGGTGTGAACGGATTTG
  R:                     GGGGTCGTTGATGGCAACA         

IL-17, interleukin 17; WT1, Wilm\'s tumor 1; F, forward; R, reverse.
